Atara biotherapeutics will present recent advancements and key upcoming milestones at the 39th annual j.p. morgan healthcare conference

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra; the “company”), a pioneer in t-cell immunotherapy leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced president and chief executive officer pascal touchon will present atara's 2020 progress and key upcoming milestones across the company's strategic prior
ATRA Ratings Summary
ATRA Quant Ranking